內分泌檢測市場規模、佔有率和成長分析：按技術、檢體類型、應用、最終用戶、分銷管道和地區分類－2026-2033年產業預測

2024 年全球內分泌檢測市場價值為 138 億美元，預計到 2033 年將成長至 290 億美元，而 2025 年為 149.9 億美元，預測期（2026-2033 年）複合年成長率為 8.6%。

全球內分泌檢測市場主要受荷爾蒙相關疾病盛行率上升的驅動，這些診斷方法正逐漸成為標準診療流程。此領域涵蓋用於評估荷爾蒙水平、自體抗體和代謝物的檢測方法和平台，以準確診斷糖尿病、甲狀腺疾病和生殖系統疾病等。及時檢測的重要性體現在其對治療決策和整體健康結果的影響。技術進步推動了檢測方法從基礎生物檢測發展到高度自動化系統，提高了檢測的靈敏度和多參數測量能力。此外，監管政策的明確和慢性病管理保險報銷範圍的擴大也進一步推動了投資。隨著遠端醫療和居家檢體採集方式的普及，新興經濟體為市場成長和擴張提供了巨大的機會。

全球內分泌檢測市場的成長要素

內分泌疾病盛行率的不斷上升推動了臨床診斷檢測的需求。醫療機構越來越重視疾病管理路徑，導致篩檢檢測數量增加。診斷數量的激增也提高了臨床醫生對定期監測必要性的認知。因此，醫院和臨床檢查室報告稱，荷爾蒙檢測和專案檢測的使用量顯著增加。這種持續的需求要求對檢測基礎設施、工作流程整合以及進行這些檢測的檢查室人員培訓進行投資，最終為市場擴張創造了機會。準確的診斷對於患者管理至關重要，因此，對有效檢測方法和相關服務的需求日益成長，進一步加速了內分泌疾病診斷產品的使用和商業化。

全球內分泌檢測市場的限制因素

全球內分泌檢測市場面臨許多限制因素，阻礙其發展。先進內分泌檢測的高成本，包括專用設備和試劑的供應，給臨床檢查室和醫療機構帶來了沉重的經濟負擔。這種情況限制了這些技術的廣泛應用。此外，大量的資本投入和持續的維護需求，使得小規模的檢查室，尤其是那些資源匱乏的實驗室，不願提供全面的檢測服務。同時，高昂的單次檢測成本也會影響採購決策和預算分配，導致更長的交付週期和更謹慎的業務擴張策略。這些經濟壓力最終會延緩新檢測方法的推出，並阻礙整體市場成長。

全球內分泌檢測市場趨勢

全球內分泌檢測市場正日益向個人化荷爾蒙譜分析轉型，這主要得益於能夠快速且有效率地評估荷爾蒙水平的技術進步。這一趨勢強調採用個人化方法診斷、監測和治療內分泌疾病，並充分利用創新的生物標記掃描和多種檢測手段。透過根據每位患者獨特的荷爾蒙功能和症狀客製化診斷測試，醫療專業人員可以最佳化治療策略並提高患者的參與度。此外，整合時間序列檢體評估和患者報告結果（PRO）能夠實現對荷爾蒙失衡的持續監測和早期發現，從而促進診斷測試開發人員和內分泌學家之間的合作，並為每位患者建立個人化的診療路徑。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球內分泌檢測市場規模：依技術分類

• 免疫檢測
• 質譜分析
• 分子診斷
• 臨床化學
• 其他

全球內分泌檢測市場規模：依樣本類型分類

• 血
• 尿
• 唾液
• 其他

全球內分泌檢測市場規模：依應用領域分類

• 內分泌疾病的診斷
• 不孕症檢查
• 糖尿病管理
• 腫瘤檢查
• 預防性健康檢查
• 其他

全球內分泌檢測市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 專科診所
• 學術研究機構
• 其他

全球內分泌檢測市場規模：依分銷管道分類

• 直銷
• 銷售代理
• 線上平台
• 其他

全球內分泌檢測市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd.
• Abbott Laboratories
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• DiaSorin SpA
• bioMerieux SA
• Randox Laboratories Ltd.
• Mindray Medical International Limited
• Becton, Dickinson and Company
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• Tosoh Corporation
• Trinity Biotech plc
• EKF Diagnostics Holdings plc
• Ortho Clinical Diagnostics Holdings plc

結論與建議

Global Endocrine Testing Market size was valued at USD 13.8 Billion in 2024 and is poised to grow from USD 14.99 Billion in 2025 to USD 29.0 Billion by 2033, growing at a CAGR of 8.6% during the forecast period (2026-2033).

The global endocrine testing market is largely propelled by the rising prevalence of hormone-related disorders, transforming these diagnostics into standard clinical practices. This field includes assays and platforms that assess hormone levels, autoantibodies, and metabolites to accurately diagnose conditions like diabetes, thyroid issues, and reproductive disorders. The significance of timely testing is underscored by its impact on treatment decisions and overall health outcomes. Advances in technology have progressed from basic bioassays to sophisticated automated systems, enhancing the sensitivity and multiplexing capabilities of tests. Moreover, regulatory clarity and increased reimbursement for chronic disease management are driving further investments. As telemedicine and home sampling methods improve accessibility, emerging economies present substantial opportunities for market growth and expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endocrine Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endocrine Testing Market Segments Analysis

Global endocrine testing market is segmented by technology, sample type, application, end user, distribution channel and region. Based on technology, the market is segmented into Immunoassay, Mass Spectrometry, Molecular Diagnostics, Clinical Chemistry and Others. Based on sample type, the market is segmented into Blood, Urine, Saliva and Others. Based on application, the market is segmented into Endocrine Disorder Diagnosis, Fertility Testing, Diabetes Management, Oncology Testing, Preventive Health Screening and Others. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Specialty Clinics, Academic & Research Institutes and Others. Based on distribution channel, the market is segmented into Direct Sales, Distributors, Online Platforms and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endocrine Testing Market

The increasing prevalence of endocrine disorders has heightened the demand for diagnostic testing within clinical settings. Healthcare providers are placing greater emphasis on disease management pathways, leading to an uptick in screening practices. This surge in diagnoses has also stimulated awareness among the clinical community regarding the necessity of routine monitoring. Consequently, hospitals and clinical laboratories have reported a significant rise in the utilization of hormonal panels and specialty assays. This ongoing demand necessitates investments in testing infrastructure, workflow integrations, and staff training in laboratories that conduct these evaluations, ultimately creating opportunities for market expansion. As accurate diagnosis is crucial in patient management, there will be a growing need for valid assays and related services, driving further use and commercialization of products aimed at diagnosing endocrine disorders.

Restraints in the Global Endocrine Testing Market

The Global Endocrine Testing market faces several significant restraints that hinder its advancement. High costs associated with advanced endocrine assays, including specialized instruments and reagent supplies, place a considerable financial strain on clinical laboratories and healthcare providers. This situation restricts the potential for widespread adoption of these technologies. Furthermore, substantial capital investments and ongoing maintenance requirements deter smaller laboratories, particularly in resource-constrained settings, from offering comprehensive testing services. Additionally, the perception of high per-test costs impacts purchasing decisions and budget allocations, resulting in prolonged procurement timelines and cautious approaches to scaling operations. Such economic pressures ultimately slow the adoption of new assays, hindering overall market growth.

Market Trends of the Global Endocrine Testing Market

The Global Endocrine Testing market is increasingly characterized by a shift towards personalized hormone profiling, driven by advancements in technology that enable rapid and efficient evaluation of hormone levels. This trend emphasizes individualized approaches to diagnosing, monitoring, and treating endocrine disorders, leveraging innovative biomarker scanning and multiplex assays. By aligning diagnostic testing with each patient's unique hormone function and symptoms, healthcare providers can optimize treatment strategies and enhance patient engagement. Additionally, the integration of longitudinal sample evaluations and patient-reported outcomes supports continuous monitoring and early identification of hormonal dysregulation, fostering collaboration between diagnostic developers and endocrinology specialists to create tailored, patient-specific care pathways.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Endocrine Testing Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunoassay
• Mass Spectrometry
• Molecular Diagnostics
• Clinical Chemistry
• Others

Global Endocrine Testing Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood
• Urine
• Saliva
• Others

Global Endocrine Testing Market Size by Application & CAGR (2026-2033)

• Market Overview
• Endocrine Disorder Diagnosis
• Fertility Testing
• Diabetes Management
• Oncology Testing
• Preventive Health Screening
• Others

Global Endocrine Testing Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Specialty Clinics
• Academic & Research Institutes
• Others

Global Endocrine Testing Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Sales
• Distributors
• Online Platforms
• Others

Global Endocrine Testing Market Size & CAGR (2026-2033)

• North America (Technology, Sample Type, Application, End User, Distribution Channel)
  • US
  • Canada
• Europe (Technology, Sample Type, Application, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Technology, Sample Type, Application, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Technology, Sample Type, Application, End User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Technology, Sample Type, Application, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics Incorporated
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Laboratory Corporation of America Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Randox Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mindray Medical International Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tosoh Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EKF Diagnostics Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ortho Clinical Diagnostics Holdings plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations